Ascletis Pharma Announces Promising Pharmacokinetic Results for ASC30 in U.S. Phase Ib Study
Reuters
Aug 28
Ascletis Pharma Announces Promising Pharmacokinetic Results for ASC30 in U.S. Phase Ib Study
Ascletis Pharma Inc. has announced favorable results from its U.S. Phase Ib multiple ascending dose study of the ASC30 oral once-daily tablet. The study demonstrated that ASC30 achieved approximately 2.3-fold to 3.3-fold greater drug exposure compared to orforglipron. The data, obtained from a randomized, double-blind, placebo-controlled trial involving participants with obesity, showed drug exposures of 3,560 ng.h/mL and 5,060 ng.h/mL for 20 mg and 40 mg doses, respectively. These results were consistent with placebo-adjusted mean body weight reductions from baseline of 4.5% and 6.5% after a 28-day treatment period. Topline data from the upcoming U.S. Phase IIa study for ASC30 in participants with obesity or overweight are expected in the fourth quarter of 2025.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ascletis Pharma Inc. published the original content used to generate this news brief on August 28, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.